EMEA-001995-PIP01-16-M03
Key facts
| Invented name |
Breyanzi
|
| Active substance |
Lisocabtagene maraleucel
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0558/2021
|
| PIP number |
EMEA-001995-PIP01-16-M03
|
| Pharmaceutical form(s) |
Dispersion for infusion
|
| Condition(s) / indication(s) |
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Bristol-Myers Squibb Pharma EEIG
E-mail: medical.information@bms.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|